Literature DB >> 7802001

Molecular and clinical study of 61 Angelman syndrome patients.

S Saitoh1, N Harada, Y Jinno, K Hashimoto, K Imaizumi, Y Kuroki, Y Fukushima, T Sugimoto, M Renedo, J Wagstaff.   

Abstract

We analyzed 61 Angelman syndrome (AS) patients by cytogenetic and molecular techniques. On the basis of molecular findings, the patients were classified into the following 4 groups: familial cases without deletion, familial cases with submicroscopic deletion, sporadic cases with deletion, and sporadic cases without deletion. Among 53 sporadic cases, 37 (70%) had molecular deletion, which commonly extended from D15S9 to D15S12, although not all deletions were identical. Of 8 familial cases, 3 sibs from one family had a molecular deletion involving only 2 loci, D15S10 and GABRB3, which define the critical region for AS phenotypes. The parental origin of deletion, both in sporadic and familial cases, was exclusively maternal and consistent with a genomic imprinting hypothesis. Among sporadic and familial cases without deletion, no uniparental disomy was found and most of them were shown to inherit chromosomes 15 from both parents (biparental inheritance). A discrepancy between cytogenetic and molecular deletion was observed in 14 (26%) of 53 patients in whom cytogenetic analysis could be performed. Ten (43%) of 23 patients with a normal karyotype showed a molecular deletion, and 4 (13%) of 30 patients with cytogenetic deletion, del(15) (q11q13), showed no molecular deletion. Most clinical manifestations, including neurological signs and facial characteristics, were not distinct in each group except for hypopigmentation of skin or hair. Familial cases with submicroscopic deletion were not associated with hypopigmentation. These findings suggested that a gene for hypopigmentation is located outside the critical region of AS and is not imprinted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802001     DOI: 10.1002/ajmg.1320520207

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  21 in total

1.  Counselling dilemmas associated with the molecular characterisation of two Angelman syndrome families.

Authors:  H L Gilbert; J L Buxton; C T Chan; T McKay; S Cottrell; S Ramsden; R M Winter; M E Pembrey; S Malcolm
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

2.  A 4 Mb cryptic deletion associated with inv(8)(q13.1q24.11) in a patient with trichorhinophalangeal syndrome type I.

Authors:  T Sasaki; H Tonoki; H Soejima; N Niikawa
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  The mechanisms involved in formation of deletions and duplications of 15q11-q13.

Authors:  W P Robinson; F Dutly; R D Nicholls; F Bernasconi; M Peñaherrera; R C Michaelis; D Abeliovich; A A Schinzel
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

Review 4.  Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion.

Authors:  A Smith; C Wiles; E Haan; J McGill; G Wallace; J Dixon; R Selby; A Colley; R Marks; R J Trent
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

5.  Angelman syndrome: Mutations influence features in early childhood.

Authors:  Wen-Hann Tan; Carlos A Bacino; Steven A Skinner; Irina Anselm; Rene Barbieri-Welge; Astrid Bauer-Carlin; Arthur L Beaudet; Terry Jo Bichell; Jennifer K Gentile; Daniel G Glaze; Lucia T Horowitz; Sanjeev V Kothare; Hye-Seung Lee; Mark P Nespeca; Sarika U Peters; Trilochan Sahoo; Dean Sarco; Susan E Waisbren; Lynne M Bird
Journal:  Am J Med Genet A       Date:  2011-01       Impact factor: 2.802

6.  Beyond Epilepsy and Autism: Disruption of GABRB3 Causes Ocular Hypopigmentation.

Authors:  Ryan J Delahanty; Yanfeng Zhang; Terry Jo Bichell; Wangzhen Shen; Kelienne Verdier; Robert L Macdonald; Lili Xu; Kelli Boyd; Janice Williams; Jing-Qiong Kang
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

7.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

Review 8.  Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms.

Authors:  Renzo Guerrini; Romeo Carrozzo; Roberta Rinaldi; Paolo Bonanni
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Molecular characterization of two proximal deletion breakpoint regions in both Prader-Willi and Angelman syndrome patients.

Authors:  S L Christian; W P Robinson; B Huang; A Mutirangura; M R Line; M Nakao; U Surti; A Chakravarti; D H Ledbetter
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

Review 10.  Epilepsy in patients with Angelman syndrome.

Authors:  Agata Fiumara; Annarita Pittalà; Mariadonatella Cocuzza; Giovanni Sorge
Journal:  Ital J Pediatr       Date:  2010-04-16       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.